| Novus Therapeutics is a pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat. Co. has two platform technologies. Co.'s primary program (OP0201) is a surfactant-based nasal aerosol drug-device combination product candidate being developed as a treatment option for patients at risk for, or with, otitis media, which is middle ear inflammation and effusion with or without infection. Co. also has a foam-based drug delivery technology platform (OP01xx), which may be developed to deliver drugs into the ear, nasal, and sinus cavities. We show 13 historical shares outstanding datapoints in our NVUS shares outstanding history coverage, used to compute NVUS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NVUS market cap history over the course of time is important for investors
interested in comparing NVUS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NVUS versus a peer is one thing; comparing
NVUS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NVUS can fluctuate over the course of history.
With this page we aim to empower investors researching NVUS by allowing them to research the NVUS market cap history.